

Lupin receives FDA approval for generic Axiron topical solution

27 October 2017 | News

Lupin's Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation



Pharma Major Lupin has received final approval for its Testosterone Topical Solution, 30 mg per actuation from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation.

Lupin's Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company's Axiron Topical Solution, 30 mg per actuation. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Testosterone Topical Solution, 30 mg per actuation, had annual sales of approximately USD 244.2 million in the US. (IMS MAT June 2017).